Enfusion — Q1 2024 Earnings Presentation
21 slides from Enfusion's earnings presentation, May 9, 2024
Slide 1: Enfusion 1Q 2024 Shareholder Letter
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Enfusion 1Q 2024 Shareholder Letter May 2024
Slide 2: Disclaimer: Forward-Looking Statements
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Disclaimer 2 Forward-Looking Statements Statements we make in this presentation may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933 (
Slide 3: Dear Shareholders
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 3 Dear Shareholders, Enfusion started the year with excellent results, positioning us to execute on our 2024 targets. We also hosted our first Investor Day this Quarter, on March 19th, in Ft Lauderdale, where we detailed the pieces no
Slide 4: Our Mission
PROPRIETARY AND CONFIDENTIAL PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. ©2023 ENFUSION. ALL RIGHTS RESERVED. 4 Our Mission To power all investment workflows with our unparalleled technology, relentless innovation, and dedicated focus on clients All Workflows Durable Financial Profile Relentles
Slide 5: Enfusion is a Unique Collaboration Platform
PROPRIETARY AND CONFIDENTIAL PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. ©2023 ENFUSION. ALL RIGHTS RESERVED. Compliance Trading Risk Operations Investor Relations Business Development Portfolio Managers Research Enfusion is a Unique Collaboration Platform Our SaaS architecture & product roadma
Slide 6: Time to disrupt the traditional asset management segment
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 6 It is our time to disrupt the traditional asset management segment the same way we disrupted the alternatives segment Untapped Upside Potential: $25B TAM $25B $15.3B $1.2B $1.3B $7.2B Private Equity & Private Credit Firms Equity Hed
Slide 7: Evolution of the Enfusion Product: 2024
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. OEMS & Compliance Portfolio Management Solutions Portfolio Construction Workbench Decision Analytics Portfolio Analytics Reporting Reference Data Book of Record Managed Services Back-office Accounting and Operations Future roadmap Inc
Slide 8: The Perfect Storm: Why Enfusion Wins
PROPRIETARY AND CONFIDENTIAL PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. ©2023 ENFUSION. ALL RIGHTS RESERVED. 8 The Perfect Storm: Why Enfusion Wins Built with multi-tenant SaaS architecture from day one Enfusion’s History Trailblazing technology foundational to future growth Client’s Race to C
Slide 9: 1Q24 Key Financial Highlights
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 1Q24 Key Financial Highlights $48.1 17.3% YoY Growth Adjusted Free Cash Flow Z00 Total Revenue Z00 Adjusted EBITDA Z00 (13.2%) FCF Conversion ($1.2) $31.9 66.3% Gross Margin Highly attractive SaaS model with combination of scale, grow
Slide 10: Strong Growth
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Strong Growth $ in millions $41.0 $42.7 $44.4 $46.5 $48.1 1Q23 2Q23 3Q23 4Q23 1Q24 Revenue 10 (1) (1) (1) $(4.1) Gross Profit and Adjusted Gross Profit (1) (1) See appendix for non-GAAP reconciliations. $27.7 $28.5 $29.9 $30.9 $31.9 $
Slide 11: Expanding Profitability
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Expanding Profitability (1) See appendix for non-GAAP reconciliations. 11 (1) (1) $(4.1) $4.7 $1.0 $2.7 $0.9 -$0.8 $5.7 $8.0 $8.2 $9.8 $9.2 1Q23 2Q23 3Q23 4Q23 1Q24 Net Income Adjusted EBITDA $0.9 $6.0 $12.1 $6.6 $1.5 -$1.6 $3.8 $9.5
Slide 12: Organic client growth and expansion continues to scale
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. $167.0 $171.2 $177.9 $185.1 $190.5 1Q23 2Q23 3Q23 4Q'23 1Q24 106.0% 101.7% 102.4% 102.1% 102.9% 1Q23 2Q23 3Q23 4Q23 1Q24 Organic client growth and expansion continues to scale 12 813 827 842 865 868 1Q23 2Q23 3Q23 4Q23 1Q24 $210 $212
Slide 13: Appendix
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Appendix
Slide 14: Consolidated Balance Sheets
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. ENFUSION, INC. CONSOLIDATED BALANCE SHEETS (dollars and shares in thousands, except par value) ASSETS Current assets: Cash and cash equivalents $ 32,894 $ 35,604 Accounts receivable, net 30,932 28,069 Prepaid expenses 5,420 5,009 Othe
Slide 15: Consolidated Statements of Operations
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. REVENUES: Platform subscriptions $ 44,689 $ 37,998 Managed services 3,177 2,744 Other 186 229 Total revenues 48,052 40,971 COST OF REVENUES: Platform subscriptions 14,394 11,675 Managed services 1,697 1,564 Other 83 63 Total cost of r
Slide 16: Consolidated Statements of Cash Flows
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Cash flows from operating activities: Net (loss) income $ (761) $ 4,694 Adjustments to reconcile net (loss) income to net cash provided by operating activities: Non-cash lease expense 1,765 1,546 Depreciation and amortization 2,674 1,
Slide 17: Reconciliations To Non-GAAP Financial Measures
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Reconciliations To Non-GAAP Financial Measures The following table reconciles net income to adjusted EBITDA: The following table reconciles gross profit to adjusted gross profit: ($ in thousands, unaudited) March 31, 2023 June 30, 202
Slide 18: Reconciliations To Non-GAAP Financial Measures
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Reconciliations To Non-GAAP Financial Measures The following table reconciles operating cash flow to adjusted free cash flow: The Company’s stock-based compensation expense was recognized in the following captions within the consolida
Slide 19: Reconciliations To Non-GAAP Financial Measures
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Reconciliations To Non-GAAP Financial Measures The following table reconciles net income to adjusted net Income which is used to calculate adjusted diluted EPS: 1 Per share amounts are based on a weighted average number of shares outs
Slide 20: Definitions
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Definitions Non-GAAP Financial Measures In addition to financial measures prepared in accordance with GAAP, this presentation and the accompanying tables include Adjusted Diluted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted
Slide 21: Definitions Continued
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Definitions Continued Adjusted Net Income and Adjusted Diluted EPS Adjusted Net Income represents net income adjusted to exclude stock-based compensation expense, the effect of foreign currency fluctuations, certain non-recurring item